RNA on Nasdaq

Atrium Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

TickerRNA on Nasdaq¹
IndustryPharmaceutical Preparations¹
HeadquartersSan Diego, California¹
Incorporated inDE²
Business address3020 Callan Road, San Diego, Ca 92121²
Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Leadership

Who has led Atrium Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief financial officer

Brendan R. Winslow2026–now

Chief financial officerBrendan R. Winslow Feb 26, 2026 to now³

Board members and other officers (10)

Chief Scientific OfficerHusam Younis Feb 26, 2026 to now⁴
OfficerKathleen P. Gallagher Feb 26, 2026 to now⁵
Chief Strategy OfficerRocio Martin Hoyos Feb 26, 2026 to now⁶
OfficerStephanie Kenney Feb 26, 2026 to now⁷
Chief Medical OfficerSteven George Hughes Feb 26, 2026 to now⁸
Board memberCarsten Boess Feb 26, 2026 to now⁹
Board memberKathleen P. Gallagher Feb 26, 2026 to now⁵
Board memberSarah Boyce Feb 26, 2026 to now¹⁰
Board memberSimona Skerjanec Feb 26, 2026 to now¹¹
Board memberTroy Edward Wilson Feb 26, 2026 to now¹²

Filings

53 filings to the SEC since October 2021: 2 quarterly reports, 7 major events, 30 insider forms, 7 large holders, 7 other. The latest 20:

Oct 9, 20268-K/A EDGAR
Oct 8, 20268-K EDGAR
Sep 22, 20264 EDGAR
Sep 22, 20264 EDGAR
Sep 22, 20264 EDGAR
Sep 22, 20264 EDGAR
Sep 22, 20264 EDGAR
Sep 22, 20264 EDGAR
Sep 22, 20264 EDGAR
Sep 22, 20264 EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 14, 2026SCHEDULE 13G EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 13, 202610-Q EDGAR
Aug 13, 20268-K EDGAR
Jul 27, 2026SCHEDULE 13G/A EDGAR
Jul 14, 20268-K EDGAR
May 15, 2026SCHEDULE 13G EDGAR
May 14, 202610-Q EDGAR
May 14, 20268-K EDGAR

The 53 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

PRICE T ROWE ASSOCIATES INC /MD/SCHEDULE 13G/A, 2 filings Apr 8, 2026 to Aug 14, 2026¹³
RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G/A, 2 filings May 15, 2026 to Aug 14, 2026¹⁴
Sessa Capital IM, L.P.SCHEDULE 13G, 1 filing Aug 14, 2026¹⁵
BlackRockSCHEDULE 13G/A, 2 filings Apr 27, 2026 to Jul 27, 2026¹⁶

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARAtrium Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGARAtrium Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGARBrendan R. Winslow, Chief financial officer
4
SEC EDGARHusam Younis, Chief Scientific Officer
5
SEC EDGARKathleen P. Gallagher, Officer
6
SEC EDGARRocio Martin Hoyos, Chief Strategy Officer
7
SEC EDGARStephanie Kenney, Officer
8
SEC EDGARSteven George Hughes, Chief Medical Officer
9
SEC EDGARCarsten Boess, Board member
10
SEC EDGARSarah Boyce, Board member
11
SEC EDGARSimona Skerjanec, Board member
12
SEC EDGARTroy Edward Wilson, Board member
13
SEC EDGARPRICE T ROWE ASSOCIATES INC /MD/ SCHEDULE 13G/A on Atrium Therapeutics, Inc.
14
SEC EDGARRA CAPITAL MANAGEMENT, L.P. SCHEDULE 13G/A on Atrium Therapeutics, Inc.
15
SEC EDGARSessa Capital IM, L.P. SCHEDULE 13G on Atrium Therapeutics, Inc.
16
SEC EDGARBlackRock SCHEDULE 13G/A on Atrium Therapeutics, Inc.